IL-23 p19
Assets acting on this target.
- Class
- IL-23 inhibitor
- Pathway
- IL-23 / Th17
IL-23 is a cytokine built from two protein subunits, p19 and p40, that together bind a receptor complex present on T helper 17 (Th17) cells and related innate immune cells. This signal sustains Th17 cells and drives their production of inflammatory messengers, notably interleukin-17 and interleukin-22, in a pathway referred to as IL-23/Th17. Overactivity of this axis contributes to chronic tissue inflammation seen in psoriasis, psoriatic arthritis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Because p19 is unique to IL-23, antibodies engineered to bind p19 neutralize IL-23 specifically, in contrast to agents that target the shared p40 subunit, which also blocks interleukin-12, a related cytokine with distinct immune functions. The rationale for p19-selective inhibition is to interrupt the Th17-driven inflammatory cycle at its source while sparing pathways not implicated in the disease, aiming for durable control of inflammation across skin, joints, and intestinal tissue. Some newer molecules combine IL-23 blockade with inhibition of other inflammatory mediators, such as TNF-alpha or TL1A, reflecting efforts to address overlapping inflammatory pathways in cases where IL-23 alone does not account for the full disease process.
IL-23 p19 drugs compared
13 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| guselkumabTremfya | Johnson & Johnson | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis |
| mirikizumabOmvoh | Eli Lilly | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Ulcerative Colitis |
| risankizumabSkyrizi | AbbVie, Boehringer Ingelheim | monoclonal antibody | Approved | Approved in Crohn's Disease; Approved in Psoriasis; Approved in Psoriatic Arthritis; Approved in Ulcerative Colitis |
| tildrakizumabIlumya | Almirall, China Medical System, Sun Pharmaceutical Industries | monoclonal antibody | Approved | Approved in Psoriasis; Approved in Psoriatic Arthritis |
| HS-20137 | Hansoh Pharmaceutical Group, Qyuns Therapeutics | monoclonal antibody | Phase 3 | Phase 3 in Psoriasis |
| JNJ-78934804 | Johnson & Johnson | Co-antibody combination (guselkumab + golimumab, SC) | Phase 3 | Phase 3 in Crohn's Disease; Phase 3 in Ulcerative Colitis |
| picankibart | Innovent Biologics | monoclonal antibody (anti-IL-23p19) | Phase 3 | Phase 3 in Psoriasis; Phase 2 in Ulcerative Colitis |
| QL2106 | Qilu Pharmaceutical | monoclonal antibody | Phase 3 | Phase 3 in Psoriasis |
| Avrukibart | Oruka Therapeutics | monoclonal antibody | Phase 2 | Phase 2 in Psoriasis |
| SHR-1139 | Jiangsu Hengrui Pharmaceuticals | monoclonal antibody (dual IL-23p19/IL-36R) | Phase 2 | Phase 2 in Psoriasis; Phase 2 in Ulcerative Colitis |
| SPY003 | Spyre Therapeutics | monoclonal antibody (anti-IL-23) | Phase 2 | Phase 2 in Ulcerative Colitis |
| SOR102 | Sorriso Pharmaceuticals | Biologic (oral dual TNFα/IL-23(p19) inhibitor) | Phase 1 | Phase 1 in Ulcerative Colitis |
| TL-003 | Bionyra Pharma, TrueLab Biopharmaceutical | bispecific antibody (anti-TL1A/IL-23, extended half-life) | Phase 1 | Phase 1 in Ulcerative Colitis |